Clinical Features and Prognostic Analysis of Newly Diagnosed Diffuse Large B-cell Lymphoma Combined with Hemophagocytic Syndrome
10.19746/j.cnki.issn1009-2137.2024.02.022
- VernacularTitle:弥漫大B细胞淋巴瘤初诊时合并噬血细胞综合征的临床特征与预后分析
- Author:
Xiao-Fang WEI
1
;
You-Fan FENG
;
Yuan FU
;
Fei LIU
;
Qiao-Lin CHEN
;
Qi-Ke ZHANG
Author Information
1. 甘肃省人民医院血液科,甘肃兰州 730000
- Keywords:
diffuse large B-cell lymphoma;
hemophagocytic syndrome;
clinical features;
prognosis
- From:
Journal of Experimental Hematology
2024;32(2):466-469
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the clinical features and prognosis between newly diagnosed diffuse large B-cell lymphoma(DLBCL)patients with and without hemophagocytic syndrome(HPS).Methods:The clinical data of 45 DLBCL patients in Gansu Provincial Hospital from January 2012 to December 2021 were retrospectively analyzed.The patients were divided into HPS group(15 cases)and non-HPS group(30 cases).The clinical features and prognosis of the two groups were compared,and survival analysis was performed using Kaplan-Meier method.Results:Patients with HSP were mostly characterized by fever,cytopenia and splenomegaly.The levels of ferritin and soluble CD25 increased in all patients.The level of fibrinogen decreased in 66.67％patients,while triglyceride increased in 53.33％patients,and bone marrow hemophagocytosis occurred in 80.00％patients.Compared with non-HSP group,the proportions of patients with advanced stage(Ann Arbor stage Ⅲ/Ⅳ)and lactate dehydrogenase(LDH)≥ 240 U/L were higher in HSP group(both P＜0.05).The median survival time of HSP group was 8.0 months,which was significantly shorter than 45.5 months of non-HSP group(P＜0.001).Conclusion:The DLBCL patients with HPS have later Ann Arbor stage,higher LDH and shorter overall survival time compared with patients without HPS.
